Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 2011. The document serves as a notification of transactions involving a Person Discharging Managerial Responsibility (PDMR) rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific share transaction.
Material Changes and Transactions
The filing details a transaction by Mr. J R Stéphenne on December 21, 2011:
- Option Exercise: Exercised options over 68,520 Ordinary shares granted on December 2, 2004, at a price of £11.23 per share.
- Share Sale: Sold 68,520 Ordinary shares on the same date at a price of £14.39 per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The transaction was notified in accordance with Disclosure Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Verify the total number of shares held by Mr. J R Stéphenne following this transaction.
- Confirm the market price of GSK shares on December 21, 2011, to contextualize the sale price of £14.39.
- Review the full terms of the GlaxoSmithKline Share Option Plan regarding the 2004 grant.